PH TSPO Study
Research type
Research Study
Full title
Evaluation of circulating endothelial inflammatory biomarkers in response to a 18kDa Translocator Protein (TSPO) ligand in pulmonary hypertension
IRAS ID
302997
Contact name
Colm McCabe
Contact email
Sponsor organisation
Imperial College London
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
0 years, 11 months, 30 days
Research summary
Pulmonary hypertension (PH) encompasses a group of severe clinical entities, in which small lung vessel loss and obstruction lead to increased pressure with in the lung blood vessels, which can lead to heart failure. There are few treatment options and those in use are based on relaxing vascular tone rather than halting or reversing the underlying disease.
Dysfunction of the endothelial cells of the lung blood vessels plays the major role in the development and progression of vascular pathology in all forms of pulmonary hypertension (PH). TSPO is a protein found in the cells of the immune system, whose levels increase in PH. In mice drugs that bind TSPO have the ability to dampen immune responses in experimental forms of PH. We would like to know whether drugs that bind TSPO have the ability to dampen the immune system in patients with PH. Imperial College, London is funding this project.
REC name
North East - York Research Ethics Committee
REC reference
21/NE/0185
Date of REC Opinion
21 Dec 2021
REC opinion
Further Information Favourable Opinion